P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiencesECCO '18 Vienna
2018
P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-upECCO '18 Vienna
2018
P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximabECCO '18 Vienna
2018
P631: Treatment of established post-operative recurrence of Crohn’s disease with anti-TNF agents: Preliminary data of a multicentre, nationwide studyECCO '18 Vienna
2018
P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitisECCO '18 Vienna
2018
P634: Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitisECCO '18 Vienna
2018
P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, NorwayECCO '18 Vienna
2018
P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitisECCO '18 Vienna
2018
P638: Nutritional status in paediatric Crohn’s disease patients: Does exclusive enteral nutrition help?ECCO '18 Vienna
2018
P639: Validation of the Quantum Blue® infliximab-level rapid test in clinical practice of patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P640: Risk of post-operative complications among Crohn’s disease patients treated pre-operatively with vedolizumab. A matched case–control studyECCO '18 Vienna
2018
P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)ECCO '18 Vienna
2018
P642: Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitisECCO '18 Vienna
2018
P643: Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patientsECCO '18 Vienna
2018
P644: Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD)ECCO '18 Vienna
2018
P645: Dynamics of proinflammatory cytokines in patients with Crohn's disease who received combined therapy with mesenchymal stromal cells of bone marrow and azathioprineECCO '18 Vienna
2018